


Annual Shareholders Meeting

TruScreen Group Limited
7 September 2021
ASX | NZX: TRU



truScreen



The path to a healthy

TruScreen's is a Cervical Cancer Screening Device which offers the latest technology in cervical screening, providing real-time detection of pre-cancerous and cancerous cervical cells to help improve the health and well-being of women around the world.

TruScreen is¹:

- Non-invasive
- Affordable
- Easy to learn
- Independent from laboratory infrastructure

future



The World Health Organisation has set a target to eliminate cervical cancer by the end of the century⁴

Traditional methods to screen women for cervical cancer have not been successful in LMICs³.

Innovative screening models are required if LMIC's are to meet WHO's three targets by 2030.



70% of women screened with high performance tests by the age of 35



90% coverage of HPV vaccination for girls <15 years old



Treatment or management of 90% of women with pre-cancer or invasive cancer



FY2021 Results

April 2020 – March 2021



FY2021 Highlights

- Market development in Central & Eastern Europe (CEE)
- Successfully dual listed on ASX
- Commenced first evaluation in the Middle East
- Completed initial phase of establishing local assembly in China
- Achieved 156 commercial installations (+100% YoY)




FY2021 Financials

KEY FINANCIALS NZD (m)	FY19 Actual	FY20 Actual	FY21 Actual	FY21/FY20
Sales	1.9	1.3	1.1	-12%
Total Revenue	3.1	2.5	1.9	-23%
COGS	1.4	0.8	0.7	
R&D	1.7	1.1	1.3	
EBITDA	(2.8)	(2.1)	(2.8)	-33%
Net Assets	11.3	7.2	11.3	
Cash	1.7	1.0	5.2	+413%

- Sales down 12% to NZ\$1.13m, COVID-19 delays in all regions
- Total revenue down 23% to NZ\$1.97m



Revenue, \$NZ



Device and SUS Revenue

- SUS revenue will grow at a higher rate than Device revenue
- SUS revenue will become a sustainable recurring revenue stream
- The device has an estimated lifetime of 5 Years, and the SUS is used once per test per patient

China Market Update

TruScreen's most established market with a growing sales trend.
China is the focus of TruScreen's commercial strategy

CHINA

FY2021 Market Progress:

- +65% commercial users
- Increase published clinical data
- COGA trial progress
- 78% of FY21 Sales

Pipeline to be driven by*:

- Local assembly
- Results from COGA project



Other Key Markets

Although impacted by COVID-19, our markets continued to make progress in FY21

Russia

- National education campaign
 - 2,800 doctors trained
- Preparation for clinical evaluations to restart

Mexico

- New distributor appointed
- +24 commercial users
- Service centre

Central Europe

- 2 new distributors appointed
- Establishment of Central Europe Advisory Board
- Dedicated Central Eastern Europe Lead

Saudi Arabia

- First clinical evaluation in the region

Vietnam


- First commercial sale
- MOH support +4 top tier hospitals



Strengthening of Medical Affairs

In FY21 TruScreen strengthened its Medical Affairs capabilities putting in place a structure for better market access and rapid growth.

- ▶ Engaged a dedicated, experienced Medical Affairs Lead in Sept 2020, Dr Beata Edling.
- ▶ Creation of International Experts Group (IEG), an independent committee to advise on;
 - ▶ International screening practices
 - ▶ Market registration & reimbursements
 - ▶ Clinical data collection, analysis, and publication
 - ▶ Partnerships
 - ▶ Screening guidelines
- ▶ Creation of CE Advisory Board to facilitate market access throughout the region
- ▶ Establishment of online training platform, to remotely train end users around the world



Our plans for FY2022


April 2021 – March 2022



Our path for growth*



Setting the foundations 2014–2020



Transformation 2020–2022



Rapid Growth 2023*+



* Subject to COVID-19 and geopolitical situation

Our Strategic Plan FY2022 + beyond

Continuous product improvement & innovation

- ▶ Ongoing improvement of products
 - ▶ Market feedback
 - ▶ Software improvements
 - ▶ Cost reduction
- ▶ Further research and development of TruScreen technology
 - ▶ KOL & IEG input
- ▶ Proactively seek opportunities for product diversification

Rapid expansion in China

- ▶ TruScreen to transition to Domestic Product
 - ▶ Local assembly
 - ▶ New sale channels
- ▶ Continue to roll-out through current pipeline (100+ hospitals)
- ▶ Strengthening of KOLs, NGOs and Govt. support
- ▶ Continuous increase in global commercial user base

Continued growth in other key markets

- ▶ Drive adoption in new markets post COVID-19
 - ▶ Focus on CE markets
 - ▶ Build local awareness through KOL engagement
 - ▶ Commencement of local evaluations and trials
- ▶ Continue to roll-out in more established markets
 - ▶ Russia, Mexico, Vietnam
- ▶ Strategic partnerships with KOL, NGOs, & Govt


FY2022 Progress

Sales **+36%** YTD vs. last year*

Unit sales of SUS **+30%** YTD vs last year*

- COGA Evaluation concluded
 - 15,661 women screened in total
 - Results are expected to be released in FY2022
- First sale to Serbia
- Held initial two International Experts Group meetings focussing on;
 - Data generation
 - Technology development
- Presented at IFCCPC 2021 Eliminating Cervical Cancer – Call for action
- Zimbabwe NAC pilot project commenced

Simple.
Life changing.





Questions

Juliet Hull
Chief Executive Officer

M – +64 27 249 3060
E – juliethull@truscreen.com

Guy Robertson
Chief Financial Officer

M – +61 407 983 270
E – guyrobertson@truscreen.com

References



1. TruScreen Ultra, *Instructions for Use*. One day training required and no need for medical or nursing degree or training.
2. WHO, *HPV and Cervical Cancer Fact sheet*, 11 November 2020, [https://www.who.int/news-room/fact-sheets/detail/human-papillomavirus-\(hpv\)-and-cervical-cancer](https://www.who.int/news-room/fact-sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer)
3. . WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO. <https://www.who.int/publications/i/item/9789240030824>
4. WHO, Unitaïd, CHAI. *Cervical Cancer Screening and Treatment of Pre-Cancerous Lesions for Secondary Prevention of Cervical Cancer, Technology Landscape*. May 2019. https://unitaid.org/assets/Cervical_Cancer_Technology-landscape-2019.pdf
5. WHO, *World Health Assembly adopts global strategy to accelerate cervical cancer elimination*, 19 August 2020, <https://www.who.int/news/item/19-08-2020-world-health-assembly-adopts-global-strategy-to-accelerate-cervical-cancer-elimination>

**A world
without
cervical
cancer.**



Disclaimers

This presentation has been prepared by TruScreen Group Limited (the "Company") and is dated 06 September 2021. This presentation contains summary information about the Company and its activities which is current as at the date of this presentation. The information in this presentation is of a general nature and does not purport to be complete nor does it contain all the information which a prospective investor may require in evaluating a possible investment in the Company. This presentation should be read in conjunction with the Company's annual report, market releases and other periodic and continuous disclosure announcements, which are available at www.nzx.com. This presentation does not constitute an offer, advertisement or invitation in any place in which, or to any person to whom, it would not be lawful to make such an offer, advertisement or invitation.

Not financial product advice

This presentation is for information purposes only and is not financial or investment advice or a recommendation to acquire the Company's securities, and has been prepared without taking into account the objectives, financial situation or needs of prospective investors. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs and consult a financial adviser, solicitor, accountant or other professional adviser if necessary.

Past performance

Any past performance information given in this presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of future performance. No representations or warranties are made as to the accuracy or completeness of such information.

Future performance

This presentation includes certain "forward-looking statements" about the Company and the environment in which the Company operates. Forward-looking information is inherently uncertain and subject to contingencies, known and unknown risks and uncertainties and other factors, many of which are outside of the Company's control, and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct. A number of important factors could cause actual results or performance to differ materially from any forward-looking statements. No assurance can be given that actual outcomes or performance will not materially differ from the forward-looking statements. The forward-looking statements are based on information available to the Company as at the date of this presentation. Except as required by law or regulation (including the Listing Rules), the Company undertakes no obligation to provide any additional or updated information whether as a result of new information, future events or results or otherwise.